Document is current

Article History

Received: 14 April 2022

Accepted: 30 August 2022

First Online: 18 September 2022

Declarations

:

: Not applicable; this is a scoping review protocol and thus does not require ethical approval.

: Not applicable.

: MA declares no competing interests. NA declares no competing interests. AB declares no competing interests. KM declares no competing interests. EA is a member of Food Allergy Canada’s Medical Advisory Board, and does research with DBV Technologies. PB reports personal fees from Novartis, Pfizer, Sanofi, DBV Technologies, ALK, and Aralez outside the submitted work and research support from Novartis, Regeneron, and Sanofi outside the submitted work. MB-S a Member of the Board, Canadian Society of Allergy and Clinical Immunology, and on the steering committee for Canada’s National Food Allergy Action Plan. EL is the co-founder and director of Science for All Audiences (SciFAA). LR declares no competing interests. VP declares no competing interests. JP is Section Head, Allied Health and Member of the Board, Canadian Society of Allergy and Clinical Immunology; sits on the steering committee for Canada’s National Food Allergy Action Plan; reports research support from CIHR; Canadian Allergy, Asthma Immunology Foundation; Research Manitoba; Children’s Hospital Research Institute of Manitoba; Manitoba Medical Services Foundation; George and Fay Yee Centre for Healthcare Innovation; and, the University of Manitoba outside the submitted work; and, personal fees from Novartis outside the submitted work.